Leap Therapeutics Faces Delisting Concerns

Ticker: CYPH · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1509745

Leap Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyLeap Therapeutics, INC. (CYPH)
Form Type8-K
Filed DateMar 17, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory

Related Tickers: LEAP

TL;DR

LEAP might get delisted, stock could be in trouble.

AI Summary

Leap Therapeutics, Inc. filed an 8-K on March 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on March 12, 2025. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, MA.

Why It Matters

This filing indicates potential issues with Leap Therapeutics' continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

FAQ

What specific rule or standard has Leap Therapeutics failed to satisfy that could lead to delisting?

The filing does not specify the exact rule or standard that Leap Therapeutics has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

What is the earliest date of the event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on March 12, 2025.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on March 17, 2025.

Where are Leap Therapeutics' principal executive offices located?

Leap Therapeutics' principal executive offices are located at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141.

What is Leap Therapeutics' state of incorporation?

Leap Therapeutics is incorporated in Delaware.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding LEAP THERAPEUTICS, INC. (CYPH).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing